ClinicalTrials.gg
CompletedNCT03733301BREEZE-AD7Updated Aug 11, 2020Results posted

A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of Baricitinib and Topical corticosteroid in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 68 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-11.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
329
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing baricitinib in Dermatitis, Atopic — 1 open to participants now, 1 under way, none of them phase 3. baricitinib · Dermatitis, Atopic.

Enrollment
8th of 11
329 · median 440
Started
2018
with 4 others
Phase 3
8 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
9 of 11
Eli Lilly and Company

Among the 11 studies testing baricitinib in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 5 that started in 2018, is one of 8 in phase 3, and was the 8th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 11 studies testing baricitinib in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing baricitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • eczema
  • atopic eczema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been diagnosed with moderate to severe atopic dermatitis for at least 12 months.
  • Have had inadequate response to existing topical (applied to the skin) medications within 6 months preceding screening.
  • Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a ).
  • Agree to use emollients daily.

Exclusion criteria

Exclusion Criteria:

  • Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, , or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.
  • A history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.
  • Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.
  • Have any serious illness that is anticipated to require the use of systemic or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
  • Have been treated with the following therapies:

    • Monoclonal antibody for less than 5 half-lives prior to randomization.
    • Received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks prior to randomization.
    • Received any parenteral corticosteroids administered by intramuscular or intravenous (IV) injection within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study.
    • Have had an intra-articular corticosteroid injection within 6 weeks prior to planned randomization.
  • Have high blood pressure characterized by a repeated systolic blood pressure >160 millimeters of mercury (mm Hg) or diastolic blood pressure >100 mm Hg.
  • Have had major surgery within the past eight weeks or are planning major surgery during the study.
  • Have experienced any of the following within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or Stage III/IV heart failure.
  • Have a history of recurrent (≥2) VTE or are considered at high risk of VTE as deemed by the investigator.
  • Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
  • Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.
  • Have specific laboratory abnormalities.
  • Have received certain treatments that are .
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
329 participants (actual)

Study arms

  • Experimental
    4 Milligram (mg) Baricitinib

    4 mg Baricitinib administered orally once daily in combination with topical corticosteroids (TCS). Placebo administered orally once daily to match 2 mg Baricitinib.

    Drug: Baricitinib · Drug: Topical corticosteroid · Drug: Placebo

  • Experimental
    2 mg Baricitinib

    2 mg Baricitinib administered orally once daily in combination with TCS. Placebo administered orally once daily to match 4 mg Baricitinib.

    Drug: Baricitinib · Drug: Topical corticosteroid · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo administered orally once daily in combination with TCS.

    Drug: Topical corticosteroid · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement

    The IGA measures investigators global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 16

  2. Percentage of Participants Achieving EASI90

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 is defined as a ≥ 90% improvement from baseline in the EASI score.

    Time frame: Week 16

  3. Percent Change From Baseline on EASI Score

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). Least Squares Mean (LSM) were calculated using mixed model repeated measures (MMRM) with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit interaction as fixed categorical effects and baseline score and baseline score-by-visit interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  4. Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the SCORAD score.

    Time frame: Week 16

  5. Percentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS)

    The Itch NRS is a patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

    Time frame: Week 16

  6. Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)

    The ADSS is a 3-item, participant-administered questionnaire developed to assess the impact of itch on sleep including difficulty falling asleep due to itch, frequency of waking due to itch, and difficulty getting back to sleep last night due to itch. Item 2 frequency of waking last night is reported by selecting the number of times they woke up each night, ranging from 0 to 29 times, where the higher a number indicates a worse outcome. The ADSS is designed to be completed daily, using a daily diary, with respondents thinking about sleep "last night." Each item is scored individually. LS Mean were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit interaction as fixed categorical effects and baseline score and baseline score-by-visit interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  7. Change From Baseline in Skin Pain NRS

    Skin Pain NRS is a patient-administered,11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Overall severity of a participant's skin pain is indicated by selecting the number, using a daily diary, that best describes the worst level of skin pain in the past 24 hours. LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by- visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  8. Percentage of Participants Achieving EASI50

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI50 is defined as a ≥ 50% improvement from baseline in the EASI score.

    Time frame: Week 16

  9. Percentage of Participants Achieving IGA of 0

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Week 16

  10. Change From Baseline in SCORAD

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by- visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  11. Percentage of Participants Achieving SCORAD90

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease: (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD90 is defined as a ≥ 90% improvement from baseline in the SCORAD score.

    Time frame: Week 16

  12. Change From Baseline in Body Surface Area (BSA) Affected

    The BSA affected by AD will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage will be reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSAhead and neck + 0.3\*BSAtrunk + 0.2\* BSAupper limbs + 0.4\*BSAlower limbs. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  13. Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment

    Percentage of participants developing skin infections requiring antibiotic treatment.

    Time frame: Week 16

  14. Mean Gram Quantity of Moderate Potency Background Topical Corticosteroid (TCS) Used (Tube Weights)

    Average weights of full tubes were used to determine the dispensed weights for each region. Returned tubes were weighed with cap without carton to determine the amount of TCS in grams (g) used at each visit. Analysis was done via analysis of variance (ANOVA), with geographic region, baseline disease severity (IGA) and treatment as factors in the model.

    Time frame: Week 0 through Week 16

  15. Percent Change From Baseline in Itch NRS

    The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM model with treatment, region, baseline disease severity, visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  16. Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)

    The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  17. Change From Baseline in the Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score

    The PGI-S-AD is a single-item question asking the participant how they would rate their overall AD symptoms over the past 24 hours, using a daily diary. The 5 categories of responses are "(0) no symptoms", "(1) very mild", "(2) mild" "(3) moderate", and "(4) severe." LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  18. Change From Baseline on the Hospital Anxiety Depression Scale (HADS)

    The HADS is a participant-rated instrument used to assess both anxiety and depression. This instrument consists of 14 item questionnaire, each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.' LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  19. Change From Baseline on the Dermatology Life Quality Index (DLQI)

    The DLQI is a simple, participant-administered,10 question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last "week." Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and at unanswered ("not relevant") responses scored as "0." Scores range from 0 to 30 (less to more impairment), and a 4-point change from baseline is considered as the minimal clinically important difference threshold. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  20. Change From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire

    The WPAI-AD participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. The WPAI-AD consists of 6 items grouped in 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment, that range from 0% to 100%, with higher values indicating greater impairment. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  21. Change From Baseline on the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm

    The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  22. Change From Baseline on the EQ-5D-5L Visual Analog Scale (VAS)

    The EQ-5D-5L is a 2-part measurement. The second part is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  23. Mean Number of Days Without Use of Background TCS

    The ANCOVA model includes treatment, region, and baseline disease severity (IGA) as factors.

    Time frame: Week 0 through Week 16

  24. Percentage of Participants Achieving IGA of 0 or 1 With a ≥ 2 Point Improvement

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Week 4

07

Results

Posted Aug 11, 2020

Participant flow

Participants who completed the 16-week treatment period had an option to enter extension study JAHN (NCT03334435).

Participant flow — Overall Study
MilestonePlacebo2 mg Baricitinib4 mg Baricitinib
Started109109111
Received one dose of study drug108109111
Completed102100107
Not completed794
Withdrew: Screen fail100
Withdrew: Non-compliance100
Withdrew: Lack of efficacy230
Withdrew: Adverse event013
Withdrew: Withdrawal by subject351

Outcome measures

PrimaryPercentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement

The IGA measures investigators global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement14.723.930.6
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.082 · Odds ratio (or): 1.88 · 95% CI 0.92 to 3.85
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.004 · Odds ratio (or): 2.77 · 95% CI 1.38 to 5.56
SecondaryPercentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)22.943.147.7
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.002 · Odds ratio (or): 2.62 · 95% CI 1.44 to 4.76
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = < 0.001 · Odds ratio (or): 3.27 · 95% CI 1.80 to 5.97
SecondaryPercentage of Participants Achieving EASI90

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 is defined as a ≥ 90% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI90
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving EASI9013.816.524.3
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.574 · Odds ratio (or): 1.24 · 95% CI 0.59 to 2.62
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.045 · Odds ratio (or): 2.07 · 95% CI 1.02 to 4.20
SecondaryPercent Change From Baseline on EASI Score

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). Least Squares Mean (LSM) were calculated using mixed model repeated measures (MMRM) with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit interaction as fixed categorical effects and baseline score and baseline score-by-visit interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline on EASI Score
percent changePlacebo2 mg Baricitinib4 mg Baricitinib
Percent Change From Baseline on EASI Score-45.08 ± 3.828-58.16 ± 3.689-67.21 ± 3.679
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.013 · Mean difference (final values): -13.08 · 95% CI -23.42 to -2.73
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -22.13 · 95% CI -32.48 to -11.78
SecondaryPercentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)

The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the SCORAD score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)7.311.018.0
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.364 · Odds ratio (or): 1.53 · 95% CI 0.61 to 3.81
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.022 · Odds ratio (or): 2.70 · 95% CI 1.15 to 6.34
SecondaryPercentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS)

The Itch NRS is a patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS)
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS)20.238.144.0
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.002 · Odds ratio (or): 2.88 · 95% CI 1.48 to 5.61
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.84 · 95% CI 1.98 to 7.46
SecondaryChange From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)

The ADSS is a 3-item, participant-administered questionnaire developed to assess the impact of itch on sleep including difficulty falling asleep due to itch, frequency of waking due to itch, and difficulty getting back to sleep last night due to itch. Item 2 frequency of waking last night is reported by selecting the number of times they woke up each night, ranging from 0 to 29 times, where the higher a number indicates a worse outcome. The ADSS is designed to be completed daily, using a daily diary, with respondents thinking about sleep "last night." Each item is scored individually. LS Mean were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit interaction as fixed categorical effects and baseline score and baseline score-by-visit interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)
units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)-0.51 ± 0.151-1.33 ± 0.147-1.42 ± 0.147
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.82 · 95% CI -1.23 to -0.41
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.92 · 95% CI -1.33 to -0.51
SecondaryChange From Baseline in Skin Pain NRS

Skin Pain NRS is a patient-administered,11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Overall severity of a participant's skin pain is indicated by selecting the number, using a daily diary, that best describes the worst level of skin pain in the past 24 hours. LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by- visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Skin Pain NRS
units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Skin Pain NRS-2.06 ± 0.231-3.22 ± 0.224-3.73 ± 0.226
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -1.15 · 95% CI -1.78 to -0.52
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -1.66 · 95% CI -2.30 to -1.30
SecondaryPercentage of Participants Achieving EASI50

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI50 is defined as a ≥ 50% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI50
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving EASI5041.364.270.3
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.57 · 95% CI 1.47 to 4.49
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.56 · 95% CI 2.00 to 6.32
SecondaryPercentage of Participants Achieving IGA of 0

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving IGA of 0
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving IGA of 02.83.78.1
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.715 · Odds ratio (or): 1.30 · 95% CI 0.32 to 5.31
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.083 · Odds ratio (or): 3.02 · 95% CI 0.86 to 10.56
SecondaryChange From Baseline in SCORAD

The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by- visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in SCORAD
units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in SCORAD-21.40 ± 1.941-29.88 ± 1.867-35.78 ± 1.862
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -8.48 · 95% CI -13.72 to -3.24
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -14.38 · 95% CI -19.62 to -9.14
SecondaryPercentage of Participants Achieving SCORAD90

The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease: (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD90 is defined as a ≥ 90% improvement from baseline in the SCORAD score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SCORAD90
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving SCORAD900.93.77.2
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.204 · Odds ratio (or): 3.21 · 95% CI 0.53 to 19.37
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.025 · Odds ratio (or): 6.99 · 95% CI 1.27 to 38.53
SecondaryChange From Baseline in Body Surface Area (BSA) Affected

The BSA affected by AD will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage will be reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSAhead and neck + 0.3\*BSAtrunk + 0.2\* BSAupper limbs + 0.4\*BSAlower limbs. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Body Surface Area (BSA) Affected
units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Body Surface Area (BSA) Affected-18.03 ± 1.888-27.00 ± 1.825-29.73 ± 1.814
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -8.97 · 95% CI -14.07 to -3.87
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -11.69 · 95% CI -16.78 to -6.61
SecondaryPercentage of Participants Developing Skin Infections Requiring Antibiotic Treatment

Percentage of participants developing skin infections requiring antibiotic treatment.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment2.84.62.7
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Fisher Exact · p = 0.721
  • Placebo vs 4 mg Baricitinib · Fisher Exact · p = >0.999
SecondaryMean Gram Quantity of Moderate Potency Background Topical Corticosteroid (TCS) Used (Tube Weights)

Average weights of full tubes were used to determine the dispensed weights for each region. Returned tubes were weighed with cap without carton to determine the amount of TCS in grams (g) used at each visit. Analysis was done via analysis of variance (ANOVA), with geographic region, baseline disease severity (IGA) and treatment as factors in the model.

Time frame:
Week 0 through Week 16
Reported as:
Least squares mean · grams
Mean Gram Quantity of Moderate Potency Background Topical Corticosteroid (TCS) Used (Tube Weights)
gramsPlacebo2 mg Baricitinib4 mg Baricitinib
Mean Gram Quantity of Moderate Potency Background Topical Corticosteroid (TCS) Used (Tube Weights)252.75 ± 17.536187.59 ± 17.508161.61 ± 17.280
Statistical analysis
  • Placebo vs 2 mg Baricitinib · ANOVA · p = 0.0073 · Mean difference (final values): -65.16 · 95% CI -112.87 to -17.65
  • Placebo vs 4 mg Baricitinib · ANOVA · p = 0.0002 · Mean difference (final values): -91.14 · 95% CI -138.43 to -43.85
SecondaryPercent Change From Baseline in Itch NRS

The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM model with treatment, region, baseline disease severity, visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Itch NRS
percent changePlacebo2 mg Baricitinib4 mg Baricitinib
Percent Change From Baseline in Itch NRS-27.00 ± 3.370-43.44 ± 3.263-51.22 ± 3.280
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = < 0.001 · Mean difference (final values): -16.44 · 95% CI -25.60 to -7.27
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = < 0.001 · Mean difference (final values): -24.22 · 95% CI -33.42 to -15.03
SecondaryChange From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)

The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)
units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)-5.60 ± 0.764-8.50 ± 0.736-10.83 ± 0.730
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.006 · Mean difference (final values): -2.90 · 95% CI -4.96 to -0.84
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = < 0.001 · Mean difference (final values): -5.23 · 95% CI -7.28 to -3.18
SecondaryChange From Baseline in the Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score

The PGI-S-AD is a single-item question asking the participant how they would rate their overall AD symptoms over the past 24 hours, using a daily diary. The 5 categories of responses are "(0) no symptoms", "(1) very mild", "(2) mild" "(3) moderate", and "(4) severe." LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score
units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline in the Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score-0.69 ± 0.094-1.06 ± 0.091-1.18 ± 0.091
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.005 · Mean difference (final values): -0.37 · 95% CI -0.63 to -0.12
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = < 0.001 · Mean difference (final values): -0.49 · 95% CI -0.75 to -0.24
SecondaryChange From Baseline on the Hospital Anxiety Depression Scale (HADS)

The HADS is a participant-rated instrument used to assess both anxiety and depression. This instrument consists of 14 item questionnaire, each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.' LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Hospital Anxiety Depression Scale (HADS)
units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Depression-1.31 ± 0.311-2.05 ± 0.298-2.33 ± 0.296
Anxiety-1.89 ± 0.304-2.70 ± 0.292-2.80 ± 0.289
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.083 · Mean difference (final values): -0.74 · 95% CI -1.57 to 0.10
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.016 · Mean difference (final values): -1.02 · 95% CI -1.85 to -0.19
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.051 · Mean difference (final values): -0.81 · 95% CI -1.63 to 0.00
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.028 · Mean difference (final values): -0.91 · 95% CI -1.72 to -0.10
SecondaryChange From Baseline on the Dermatology Life Quality Index (DLQI)

The DLQI is a simple, participant-administered,10 question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last "week." Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and at unanswered ("not relevant") responses scored as "0." Scores range from 0 to 30 (less to more impairment), and a 4-point change from baseline is considered as the minimal clinically important difference threshold. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Dermatology Life Quality Index (DLQI)
units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline on the Dermatology Life Quality Index (DLQI)-5.58 ± 0.608-7.50 ± 0.584-8.89 ± 0.851
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.022 · Mean difference (final values): -1.92 · 95% CI -3.56 to -0.28
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = < 0.001 · Mean difference (final values): -3.31 · 95% CI -4.94 to -1.68
SecondaryChange From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire

The WPAI-AD participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. The WPAI-AD consists of 6 items grouped in 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment, that range from 0% to 100%, with higher values indicating greater impairment. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire
units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Absenteeism-6.27 ± 1.897-4.25 ± 1.741-5.29 ± 1.737
Presenteeism-13.15 ± 3.203-21.28 ± 2.978-23.89 ± 2.955
Work Productivity Loss-14.25 ± 3.300-22.17 ± 3.070-24.96 ± 3.051
Activity Impairment-16.75 ± 2.570-26.55 ± 2.458-27.25 ± 2.447
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.435 · Mean difference (final values): 2.01 · 95% CI -3.06 to 7.08
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.706 · Mean difference (final values): 0.97 · 95% CI -4.10 to 6.04
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.066 · Mean difference (final values): -8.12 · 95% CI -16.78 to 0.54
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.014 · Mean difference (final values): -10.73 · 95% CI -19.30 to -2.17
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.081 · Mean difference (final values): -7.93 · 95% CI -16.84 to 0.99
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.018 · Mean difference (final values): -10.71 · 95% CI -19.55 to 1.88
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.006 · Mean difference (final values): -9.80 · 95% CI -16.71 to -2.89
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -10.50 · 95% CI -17.39 to -3.61
SecondaryChange From Baseline on the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm

The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline on the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm
units on a scalePlacebo2 mg Baricitinib4 mg Baricitinib
Health State Index Score (US Algorithm)0.09 ± 0.0130.12 ± 0.0120.14 ± 0.012
Health State Index Score (UK Algorithm)0.13 ± 0.0180.17 ± 0.0170.21 ± 0.017
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.176 · Mean difference (final values): 0.02 · 95% CI -0.01 to 0.06
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.004 · Mean difference (final values): 0.05 · 95% CI 0.02 to 0.09
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.176 · Mean difference (final values): 0.03 · 95% CI -0.01 to 0.08
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.003 · Mean difference (final values): 0.07 · 95% CI 0.02 to 0.12
SecondaryChange From Baseline on the EQ-5D-5L Visual Analog Scale (VAS)

The EQ-5D-5L is a 2-part measurement. The second part is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · millimeters
Change From Baseline on the EQ-5D-5L Visual Analog Scale (VAS)
millimetersPlacebo2 mg Baricitinib4 mg Baricitinib
Change From Baseline on the EQ-5D-5L Visual Analog Scale (VAS)11.00 ± 1.90315.12 ± 1.80617.06 ± 1.805
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.113 · Mean difference (final values): 4.12 · 95% CI -0.98 to 9.23
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.020 · Mean difference (final values): 6.06 · 95% CI 0.96 to 11.16
SecondaryMean Number of Days Without Use of Background TCS

The ANCOVA model includes treatment, region, and baseline disease severity (IGA) as factors.

Time frame:
Week 0 through Week 16
Reported as:
Least squares mean · days
Mean Number of Days Without Use of Background TCS
daysPlacebo2 mg Baricitinib4 mg Baricitinib
Mean Number of Days Without Use of Background TCS12.45 ± 3.1722.49 ± 3.1629.78 ± 3.12
Statistical analysis
  • Placebo vs 2 mg Baricitinib · ANCOVA · p = 0.022 · Mean difference (final values): 10.04 · 95% CI 1.46 to 18.36
  • Placebo vs 4 mg Baricitinib · ANCOVA · p = < 0.001 · Mean difference (final values): 17.33 · 95% CI 8.79 to 25.88
SecondaryPercentage of Participants Achieving IGA of 0 or 1 With a ≥ 2 Point Improvement

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving IGA of 0 or 1 With a ≥ 2 Point Improvement
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving IGA of 0 or 1 With a ≥ 2 Point Improvement5.517.419.8
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.006 · Odds ratio (or): 3.83 · 95% CI 1.46 to 10.03
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.002 · Odds ratio (or): 4.58 · 95% CI 1.77 to 11.87

Adverse events

Collected over Baseline up to 20 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/108 (0%)4/108 (3.7%)15/108 (13.9%)
2 mg Baricitinib0/109 (0%)2/109 (1.8%)24/109 (22%)
4 mg Baricitinib0/111 (0%)4/111 (3.6%)26/111 (23.4%)
Most frequent serious events
Most frequent serious events
EventPlacebo2 mg Baricitinib4 mg Baricitinib
Abdominal painGastrointestinal disorders1/1080/1090/111
Eye infection toxoplasmalInfections and infestations1/1080/1090/111
Postoperative abscessInfections and infestations1/1080/1090/111
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1080/1090/111
Skin lacerationInjury, poisoning and procedural complications0/1081/1090/111
Dermatitis atopicSkin and subcutaneous tissue disorders0/1081/1090/111
CataractEye disorders0/1080/1091/111
Back painMusculoskeletal and connective tissue disorders0/1080/1091/111
AsthmaRespiratory, thoracic and mediastinal disorders0/1080/1091/111
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1080/1091/111
Most frequent other events
Most frequent other events
EventPlacebo2 mg Baricitinib4 mg Baricitinib
NasopharyngitisInfections and infestations13/10812/10917/111
Upper respiratory tract infectionInfections and infestations2/1088/1093/111
FolliculitisInfections and infestations0/1084/1096/111

Baseline characteristics

All randomized participants.

Age, Categorical
Age, Categorical(Participants)Placebo2 mg Baricitinib4 mg BaricitinibTotal
<=18 years0000
Between 18 and 65 years106105111322
>=65 years3407
Sex: Female, Male
Sex: Female, Male(Participants)Placebo2 mg Baricitinib4 mg BaricitinibTotal
Female383936113
Male717075216
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo2 mg Baricitinib4 mg BaricitinibTotal
Asian575754168
Multiple62311
White465054150
Region of Enrollment
Region of Enrollment(Participants)Placebo2 mg Baricitinib4 mg BaricitinibTotal
Argentina861125
South Korea29191563
Austria2158
Japan21202263
Taiwan9121536
Poland119626
Italy76619
Australia414927
Germany12181747
Spain64515
08

Study locations

68 sites
  • Centro de Investigaciones Metabólicas (CINME) - Comite
    Ciudad Autonoma Buenos Aires, C1056ABJ, Argentina
  • Fundacion CIDEA
    Ciudad Autonoma Buenos Aires, C1121ABE, Argentina
  • Instituto de Neumonología y Dermatología
    Ciudad Autonoma Buenos Aires, C1425BEA, Argentina
  • Psoriahue Medicina Interdisciplinaria
    Ciudad Autonoma Buenos Aires, C1425DKG, Argentina
  • Parra Dermatología
    Mendoza, 5500, Argentina
  • Woden Dermatology
    Phillip, Australian Capital Territory 2606, Australia
  • Skin & Cancer Foundation Australia
    Westmead, New South Wales 2145, Australia
  • The Skin Centre
    Benowa, Queensland 4217, Australia
  • Veracity Clinical Research Pty Ltd
    Woolloongabba, Queensland 4102, Australia
  • Clinical Trials SA Pty Ltd
    Adelaide, South Australia 5073, Australia
  • Skin and Cancer Foundation Inc.
    Melbourne, Victoria 3053, Australia
  • Fremantle Dermatology
    Perth, Western Australia 6160, Australia
  • Universitätsklinikum Graz
    Graz, Steiermark 8036, Austria
  • Universitätsklinikum Heidelberg
    Heidelberg, Baden-Württemberg 69120, Germany
  • Klinikum der Universität München
    München, Bayern 80337, Germany
  • Rosenpark Research Geschäftsbereich der Rosenparkklinik GmbH
    Darmstadt, Hessen 64283, Germany
  • Dermatologisches Zentrum Osnabrück Nord
    Bramsche, Niedersachsen 49565, Germany
  • Universitätsklinikum Aachen - UKA
    Aachen, Nordrhein-Westfalen 52074, Germany
  • Universitaetsklinikum Essen
    Essen, Nordrhein-Westfalen 45147, Germany
  • Universitätsklinikum Münster
    Münster, Nordrhein-Westfalen 48149, Germany
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, Schleswig-Holstein 23538, Germany
  • Charité Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • TFS Trial Form Support GmbH
    Hamburg, 20537, Germany
  • Policlinico Univ. Agostino Gemelli
    Roma, Lazio 00168, Italy
  • Istituto Clinico Humanitas
    Rozzano, Milano 20089, Italy
  • Azienda Ospedaliera Universitaria Ospedale San Martino di Genova
    Genova, 16132, Italy
  • Azienda Ospedaliera - Universitaria Pisana
    Pisa, 56126, Italy
  • ULSS 8 UOC Dermatologia Viale Rodolfi, 37
    Vicenza, 36100, Italy
  • Kawashima Dermatology Clinic
    Ichikawa-shi, Chiba 272-0033, Japan
  • Medical Corporation Soleil Miyata Dermatology Clinic
    Matsudo-shi, Chiba 271-0092, Japan
  • Yamano Dermatological Clinic
    Dazaifu, Fukuoka 818-0104, Japan
  • Tashiro Dermatological Clinic
    Iizuka-city, Fukuoka 820-0040, Japan
  • Shibaki Dermatology Clinic
    Sapporo, Hokkaido 006 0022, Japan
  • Sapporo Skin Clinic
    Sapporo, Hokkaido 060-0063, Japan
  • Queen's Square Dermatology and Allergology
    Nishi-ku, Yokohama-city, Kanagawa 220-6208, Japan
  • Yoshioka Dermatology Clinic
    Neyagawa-shi, Osaka 572-0838, Japan
  • Senri-Chuo Hanafusa Dermatology Clinic
    Toyonaka-shi, Osaka 560-0085, Japan
  • JA Shizuoka Kohseiren Enshu Hospital
    Hamamatsu-shi, Shizuoka 430-0929, Japan
  • Iidabashi Clinic
    Chiyoda-ku, Tokyo 102-0072, Japan
  • Tokyo Teishin Hospital
    Chiyoda-Ku, Tokyo 102-8798, Japan
  • Hosono Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Oizumi Hanawa Clinic
    Nerima-ku, Tokyo 178-0063, Japan
  • Yamate Dermatological Clinic
    Shinjuku, Tokyo 169-0075, Japan
  • Tachikawa Dermatology Clinic
    Tachikawa-shi, Tokyo 190-0023, Japan
  • Shirasaki Clinic
    Takaoka-shi, Toyama 9330871, Japan
  • Korea University Ansan Hospital
    Ansan-si, Gyeonggi-do 15355, Korea, Republic of
  • Dongguk University Ilsan Hospital
    Goyang, Gyeonggi-do 10326, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, Korea 21565, Korea, Republic of
  • Severance Hospital Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Konkuk University Hospital
    Seoul, 05030, Korea, Republic of
  • Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Chungang University Hospital
    Seoul, 06973, Korea, Republic of
  • Hallym University Kangnam Sacred Heart Hospital
    Seoul, 07441, Korea, Republic of
  • Dermed Centrum Medyczne Sp. z o.o.
    Lodz, 90-265, Poland
  • Lubelskie Centrum Diagnostyczne
    Swidnik, 21-040, Poland
  • Centrum Medyczne AMED
    Warszawa, 01-518, Poland
  • Centrum Medyczne Evimed
    Warszawa, 02-625, Poland
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Reina Sofia
    Cordoba, 14004, Spain
  • Hospital De Gran Canaria Dr. Negrin
    Las Palmas de Gran Canaria, 35010, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Chang Gung Memorial Hospital - Kaohsiung
    Kaohsiung, 83301, Taiwan
  • Taipei Medical University- Shuang Ho Hospital
    New Taipei City, 23561, Taiwan
  • Chung Shan Medical University Hospital
    Taichung City, 40201, Taiwan
  • National Taiwan University Hospital
    Taipei City, 10048, Taiwan
  • Chang Gung Memorial Hospital - Taipei
    Taipei, 10508, Taiwan
  • Chang Gung Memorial Hospital - Linkou
    Taoyuan, (r.o.c.), 333, Taiwan
09

References and documents

Publications

  • Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H. Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials. Dermatol Ther (Heidelb). 2022 Dec;12(12):2765-2779. doi: 10.1007/s13555-022-00828-5. Epub 2022 Oct 18. PubMed 36255569 ↗
  • Thyssen JP, Buhl T, Fernandez-Penas P, Kabashima K, Chen S, Lu N, DeLozier AM, Casillas M, Stander S. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7. Dermatol Ther (Heidelb). 2021 Oct;11(5):1599-1611. doi: 10.1007/s13555-021-00577-x. Epub 2021 Jul 18. PubMed 34275122 ↗
  • Buhl T, Rosmarin D, Serra-Baldrich E, Fernandez-Penas P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. Dermatol Ther (Heidelb). 2021 Jun;11(3):971-982. doi: 10.1007/s13555-021-00534-8. Epub 2021 Apr 25. PubMed 33899152 ↗
  • King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. Am J Clin Dermatol. 2021 May;22(3):395-405. doi: 10.1007/s40257-021-00602-x. Epub 2021 Apr 7. PubMed 33826132 ↗
  • Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, Kaszuba A, Kolodsick J, Yang FE, Gamalo M, Brinker DR, DeLozier AM, Janes JM, Nunes FP, Thyssen JP, Simpson EL. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020 Dec 1;156(12):1333-1343. doi: 10.1001/jamadermatol.2020.3260. PubMed 33001140 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jul 2019, 8 months.

Results were first posted in Aug 2020, 1 year after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 8 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2018
First posted
Nov 7, 2018
StartActual
Nov 16, 2018
Primary completionActual
Jul 29, 2019
CompletionActual
Aug 22, 2019
Results first posted
Aug 11, 2020
Last update
Aug 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03733301
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 7, 2018
Start date
Nov 16, 2018
Primary completion
Jul 29, 2019
Completion
Aug 22, 2019
Results posted
Aug 11, 2020
Last update
Aug 11, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion